Alirocumab primarily lowers which lipid parameter?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Alirocumab primarily lowers which lipid parameter?

Alirocumab is a PCSK9 inhibitor that increases the number of LDL receptors on liver cells by preventing PCSK9 from promoting LDL receptor degradation. With more receptors available, more LDL particles are cleared from the blood, leading to a large drop in LDL cholesterol. This is the primary lipid parameter affected, while HDL-C stays largely unchanged and total cholesterol falls mainly because LDL-C is reduced. So the parameter most directly decreased by alirocumab is LDL-C.

Alirocumab is a PCSK9 inhibitor that increases the number of LDL receptors on liver cells by preventing PCSK9 from promoting LDL receptor degradation. With more receptors available, more LDL particles are cleared from the blood, leading to a large drop in LDL cholesterol. This is the primary lipid parameter affected, while HDL-C stays largely unchanged and total cholesterol falls mainly because LDL-C is reduced. So the parameter most directly decreased by alirocumab is LDL-C.

More practice questions